Antimicrobial therapy for chronic osteomyelitis in adults: Role of the quinolones

Research output: Contribution to journalReview article

85 Citations (Scopus)

Abstract

The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.

Original languageEnglish (US)
Pages (from-to)1327-1333
Number of pages7
JournalClinical Infectious Diseases
Volume25
Issue number6
DOIs
StatePublished - Jan 1 1997

Fingerprint

Quinolones
Osteomyelitis
Lactams
Debridement
Prosthesis-Related Infections
Therapeutics
Rifampin
Clinical Trials
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Antimicrobial therapy for chronic osteomyelitis in adults : Role of the quinolones. / Rissing, John Peter.

In: Clinical Infectious Diseases, Vol. 25, No. 6, 01.01.1997, p. 1327-1333.

Research output: Contribution to journalReview article

@article{9884e304450d449c9fa847f8ec612bc2,
title = "Antimicrobial therapy for chronic osteomyelitis in adults: Role of the quinolones",
abstract = "The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.",
author = "Rissing, {John Peter}",
year = "1997",
month = "1",
day = "1",
doi = "10.1086/516150",
language = "English (US)",
volume = "25",
pages = "1327--1333",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Antimicrobial therapy for chronic osteomyelitis in adults

T2 - Role of the quinolones

AU - Rissing, John Peter

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.

AB - The development of antimicrobial therapy for osteomyelitis is reviewed. The disease, especially when chronic, is notoriously resistant to antibiotic therapy. The duration of disease defining chronicity has decreased considerably in the last 30 years. Successful therapy reflects increased appreciation of the combined roles of surgical debridement and prolonged antimicrobial courses. Parenteral high-dose β-lactam agents yield clinical success for many patients with chronic osteomyelitis, particularly with prolonged administration and surgical debridement. Over the last decade, the initial success of oral quinolone therapy for gram-negative osteomyelitis was exploited further for staphylococcal diseases. Open clinical trials and comparative trials suggest success rates approximating those achieved with parenteral β-lactams, particularly with appropriate surgery and adequate duration of therapy. The early results with quinolones and rifampin for prosthesis-related infection are encouraging. Overall, oral quinolones provide a new and frequently proportionate response to a disease that is difficult to treat.

UR - http://www.scopus.com/inward/record.url?scp=0031436961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031436961&partnerID=8YFLogxK

U2 - 10.1086/516150

DO - 10.1086/516150

M3 - Review article

C2 - 9431371

AN - SCOPUS:0031436961

VL - 25

SP - 1327

EP - 1333

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -